Patient characteristics
| Variable . | T-cell depletion . | Immunosuppressive medication . | P . |
|---|---|---|---|
| N (%) | 48 (33) | 98 (67) | |
| Age, median years (range) | 48 (21-60) | 42 (20-61) | — |
| 50 y or younger (%) | 30 (62) | 71 (72) | .25 |
| Older than 50 y (%) | 18 (38) | 27 (28) | |
| Sex match (%) | |||
| M-M | 19 (39) | 31 (32) | .39 |
| M-F | 11 (23) | 21 (21) | |
| F-M | 10 (21) | 17 (17) | |
| F-F | 8 (17) | 29 (30) | |
| Mismatched, N (%) | 1 (2) | 16 (16) | .01 |
| CMV, patient/donor (%) | |||
| Neg/Neg | 20 (42) | 32 (33) | .43 |
| Pos/Neg | 6 (12) | 22 (22) | |
| Neg/Pos | 13 (27) | 29 (30) | |
| Pos/Pos | 9 (19) | 15 (15) | |
| Conditioning regimen (%) | |||
| Cyclophosphamide/total body irradiation | 46 (96) | 95 (97) | .66 |
| Busulfan/cyclophosphamide | 2 (4) | 3 (3) | — |
| Total lymphoid irradiation* | |||
| 4.5 Gy | 25 (57) | N/A | |
| 7.5 Gy | 19 (43) | N/A | |
| Disease risk (%) | |||
| Low risk | 22 (46) | 24 (24) | .01 |
| High risk | 26 (54) | 74 (76) | |
| Disease (%) | |||
| CML | 10 (21) | 45 (46) | < .01 |
| AML | 15 (31) | 20 (20) | |
| MDS | 4 (8) | 13 (13) | |
| CLL | 0 (0) | 1 (1) | |
| MM | 1 (2) | 0 (0) | |
| NHL | 4 (8) | 5 (5) | |
| ALL | 14 (29) | 9 (9) | |
| Other (HL, other leukemia, other) | 0 (0) | 5 (5) | |
| Median follow-up, mo (range) for alive patients | 14.8 (6.1-36.5) | 18.7 (8.4-39.2) | .25 |
| Variable . | T-cell depletion . | Immunosuppressive medication . | P . |
|---|---|---|---|
| N (%) | 48 (33) | 98 (67) | |
| Age, median years (range) | 48 (21-60) | 42 (20-61) | — |
| 50 y or younger (%) | 30 (62) | 71 (72) | .25 |
| Older than 50 y (%) | 18 (38) | 27 (28) | |
| Sex match (%) | |||
| M-M | 19 (39) | 31 (32) | .39 |
| M-F | 11 (23) | 21 (21) | |
| F-M | 10 (21) | 17 (17) | |
| F-F | 8 (17) | 29 (30) | |
| Mismatched, N (%) | 1 (2) | 16 (16) | .01 |
| CMV, patient/donor (%) | |||
| Neg/Neg | 20 (42) | 32 (33) | .43 |
| Pos/Neg | 6 (12) | 22 (22) | |
| Neg/Pos | 13 (27) | 29 (30) | |
| Pos/Pos | 9 (19) | 15 (15) | |
| Conditioning regimen (%) | |||
| Cyclophosphamide/total body irradiation | 46 (96) | 95 (97) | .66 |
| Busulfan/cyclophosphamide | 2 (4) | 3 (3) | — |
| Total lymphoid irradiation* | |||
| 4.5 Gy | 25 (57) | N/A | |
| 7.5 Gy | 19 (43) | N/A | |
| Disease risk (%) | |||
| Low risk | 22 (46) | 24 (24) | .01 |
| High risk | 26 (54) | 74 (76) | |
| Disease (%) | |||
| CML | 10 (21) | 45 (46) | < .01 |
| AML | 15 (31) | 20 (20) | |
| MDS | 4 (8) | 13 (13) | |
| CLL | 0 (0) | 1 (1) | |
| MM | 1 (2) | 0 (0) | |
| NHL | 4 (8) | 5 (5) | |
| ALL | 14 (29) | 9 (9) | |
| Other (HL, other leukemia, other) | 0 (0) | 5 (5) | |
| Median follow-up, mo (range) for alive patients | 14.8 (6.1-36.5) | 18.7 (8.4-39.2) | .25 |
CMV indicates cytomegalovirus; CML, chronic myelogenous leukemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; ALL, acute lymphocytic leukemia; and HL, Hodgkin lymphoma.
Of 48 TCD patients, 44 (92%) also had total lymphoid irradiation.